January 27, 2015
Astellas Pharma has said that Xtandi (enzalutamide), an oral androgen receptor inhibitor, significantly prolonged progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer, in comparison with the anti-androgen agent bicalutamide in a PII clinical study. In the PII TERRAIN...read more